Smobio Technology Inc
TTPEX:742229.80
TWD
+0.10
(+0.34%)
Smobio Technology Inc
TPEX:7422
(Taipei Exchange)
Recent
price
29.80
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Smobio Technology Inc is a Taiwan-based biotechnology company that engages in the research, development, manufacture, and distribution of molecular biology reagents, laboratory research tools, and diagnostic assay components for life sciences research and clinical applications. Founded in 2004 and headquartered in Hsinchu County, Taiwan, the company operates primarily within the biotechnology and life science research tools industry, serving academic institutions, contract research organizations, diagnostic developers, and biopharmaceutical laboratories worldwide. Smobio Technology categorizes its primary product portfolio into: DNA ladders and molecular weight markers, including the ExcelBand and FluoroBand series for gel electrophoresis analysis; protein ladders and molecular standards, featuring pre-stained and multi-color protein markers such as the ExcelBand series; polymerase chain reaction (PCR) and real-time quantitative PCR (qPCR) reagents, encompassing ExcelTaq DNA polymerases, master mixes, reverse transcriptases, and cDNA synthesis kits; nucleic acid and protein staining reagents, such as FluoroStain and FluoroVue gel stains; Western blot and immunodetection solutions, including enhanced chemiluminescence (ECL) substrates, transfer buffers, and protein quantification assays; laboratory instruments and visualization devices, including blue light LED transilluminators such as the B-BOX system; and customized contract manufacturing, original equipment manufacturing (OEM), and original design manufacturing (ODM) reagent formulation services for global life science brands. In recent developments, the company has expanded its manufacturing operations to meet rising international demand for diagnostic-grade enzymes and master mixes, accelerated the launch of high-sensitivity RT-qPCR and lyophilization-ready reagent formulations for point-of-care molecular diagnostic developers, broadened its distribution partnerships across key markets in North America, Europe, and the Asia-Pacific region, and enhanced its quality management infrastructure to align with ISO 13485 standards for clinical and translational research supply chains.